Table 1 |
|||
|
Patients analyzeda |
|||
|
Patient characteristics |
ABCoN (N = 98) |
Nested I (N = 64) |
Control (N = 102) |
|
|
|||
|
Mean (SD) age, years |
54.8 (12.8) |
52.6 (13.3) |
55.9 (13.0) |
|
Sex (female), n (%) |
75 (78)b |
53 (83) |
77.4 |
|
Mean (SD) disease duration, years |
10.3 (9.0) |
9.2 (11.6)b |
NA |
|
Mean (SD) disease activity, DAS28 score |
5.16 (0.95) |
5.62 (0.91) |
NA |
|
RF-positive, n (%) |
81 (87.1) |
45 (70.3)b |
NA |
|
ACPA-positive, n (%) |
75 (80.5) |
37 (74.0)b |
NA |
|
Mean (SD) sG0/G1 |
1.37 (0.42) |
1.38 (0.41) |
1.02 (0.25) |
|
|
|||
|
a ABCoN, Autoimmune Biomarkers Collaborative Network; ACPA, Anti-Citrullinate Peptide Antibody; DAS28, 28-joint Disease Activity Score; RF, rheumatoid factor; sG0/G1, ratio of agalactosylated to monogalactosylated N-glycans in serum. bFractions represent proportions within available data. ABCoN gender data available in 96 patients; Nested I, disease duration available in 62 patients, RF in 63 and ACPA in 50 patients. |
|||
|
Ercan et al. Arthritis Research & Therapy 2012 14:R43 doi:10.1186/ar3756 |
|||
